Clinical Trials Logo

Filter by:
NCT ID: NCT02196142 Completed - Clinical trials for Psychological Stress

Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence

CAR-Bern 2013
Start date: November 2014
Phase: Phase 3
Study type: Interventional

To investigate the effects of cortisol on alcohol craving and stress reactivity in alcohol addicted subjects. Randomized, double-blind, placebo-controlled, cross-over, single administration of study medication. Study hypothesis: Cortisol has an inhibiting effect on alcohol craving and stress reactivity in alcohol dependent subjects.

NCT ID: NCT02194842 Active, not recruiting - Prostate Cancer Clinical Trials

Phase III Radium 223 mCRPC-PEACE III

PEACE III
Start date: October 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) compared to enzalutamide single agent in CRPC patients metastatic to bone

NCT ID: NCT02194426 Completed - Neoplasms Clinical Trials

First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients

Start date: July 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is looking at a new DARPin® drug candidate, called MP0250. There is evidence from preclinical studies that MP0250 may be effective in the treatment of cancer. This is the first study of MP0250 in humans and its main purpose is to test its safety and tolerability in patients with cancer. This study will also examine how the drug is changed by and removed from the body and look for indicators that the drug may be effective against cancer. This study will test several different dose levels of the study drug to determine the safety and tolerability profile of the drug.

NCT ID: NCT02193503 Active, not recruiting - Cancer Clinical Trials

MVX-ONCO-1 in Patients With Solid Tumor

Start date: March 2014
Phase: Phase 1
Study type: Interventional

The objectives are to assess the safety and tolerability of 6 vaccine doses of MVX-ONCO-1, administered sub-cutaneously (injections and capsules implantations), in patients with advanced metastatic solid tumor in progression who are not or not any longer amenable to any standard therapy of their tumour disease.

NCT ID: NCT02193438 Completed - Healthy Clinical Trials

Physiologic Effect of Spices Ingestion

Start date: May 2011
Phase: N/A
Study type: Interventional

Human studies have shown that capsaicin, a compound extracted from chilly peppers, can stimulate certain physiologic functions (for example, energy expenditure, thermogenesis, lipid oxidation, heart rate, etc.). The purpose of this study is to measure the impact of ingesting various spicy molecules on a set of physiologic parameters compared to a placebo. The molecules were selected for their different sensory properties. The results of this study will allow us to implement an effective method for measuring the impact of ingesting spices on certain body functions (for example, metabolism and autonomic nervous system activity). This study will also allow us to identify the beneficial properties of eating certain spices.

NCT ID: NCT02192125 Completed - Stroke Clinical Trials

REWIRE - Rehabilitative Wayout In Responsive Home Environments, A Pilot Trial

REWIRE
Start date: January 2014
Phase: Phase 0
Study type: Interventional

The study examines the possible application of the rehabilitation platform REWIRE.

NCT ID: NCT02189564 Completed - Motor Learning Clinical Trials

Rewarding Feedback in Motor Learning and Rehabilitation

KFSP-REWARD
Start date: January 2014
Phase: N/A
Study type: Interventional

The effect of rewarding vs. non-rewarding feedback on acquisition of a motor skill is investigated in a single blinded parallel group design. Reward consists of performance dependent monetary reward, or of knowledge of performance in selected (above average) trials. The investigators hypothesize improved motor skill learning and higher involvement of the dopaminsrgic system under rewarding vs. non-rewarding conditions.

NCT ID: NCT02189551 Terminated - Clinical trials for Post Stroke Gait Training

Advanced Robotic Training With Additional Degrees of Freedom: Towards a Free-walking System

LOKOMAT
Start date: June 2014
Phase: N/A
Study type: Interventional

The objective of the study is to compare a new medical devices with an established medical device for lower limb rehabilitation regarding training outcome and patient comfort / patient satisfaction (primary objective) and treatment effect (exploratory objective). Primary study endpoints will be a significantly higher rated patient comfort and or patient satisfaction using the new versions, compared with the established Lokomat. Furthermore, muscle activity and kinematic movement patterns will be expected to show more involved muscle groups and a walking pattern involving more degrees of freedom during use of the new version compared with the established Lokomat. Exploratory endpoints will be a significantly stronger involvement of muscles needed for balance, more physiological walking patterns and more change on the lateral positioning of the feet due to training with the new version, compared with the established Lokomat.

NCT ID: NCT02189239 Completed - Clinical trials for The Primary Condition Studied for This Trial is Acute Stress

Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress

Start date: January 2015
Phase: Phase 4
Study type: Interventional

The objective of the STRESS trial is to investigate in a mode of action setting the effect of Zeller Entspannung film coated tablets on saliva cortisol response versus Placebo after acute stress in healthy male volunteers. In addition, data on safety and tolerability of Zeller Entspannung will be obtained. A third arm including no treatment is tested as well. Approximately 72 healthy volunteers will be included into this randomized, double blind study. Study duration will be 7 days, study medication intake will be over 4 days: participants will take the medication one tablet three times a day (morning, midday, evening) the first 3 days, whereas on day 4 only two tablets will be taken (morning and midday).

NCT ID: NCT02188537 Completed - Myeloma Clinical Trials

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Start date: December 2, 2014
Phase: Phase 2
Study type: Interventional

Trial objectives: To decide whether the addition of nelfinavir to the approved antimyeloma therapy with bortezomib and dexamethasone has sufficient activity in proteasome inhibitor-resistant myeloma patients to merit further clinical investigation in a prospective controlled trial. Additional research questions: To collect myeloma cell samples from proteasome inhibitor-resistant myeloma patients for the assessment of the biology of proteasome inhibitor resistance and the identification of predictive markers for response to nelfinavir-based antimyeloma therapy.